[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Yasuda S, Kojima A, Maeno Y, Oki N, Miyahara Y, Sudo T, Takekida S, Yamaguchi S, Nishimura R: Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis. Kobe J Med Sci; 2006;52(1-2):9-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis.
  • From January 1990 to December 2004, the prognosis of 28 patients with stage Ib1 adenosquamous cell carcinoma (ASC) were assessed in comparison with those of matched counterparts of pure adenocarcinoma (ADC) and squamous cell carcinoma (SCC).
  • There was also no significant difference in the incidence of lymphatic or vascular space involvement (LVSI) and depth of stromal invasion between three cell types.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lymphatic Metastasis / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Pelvis. Prognosis. Retrospective Studies. Survival Rate


2. Meng YH, Li S, Hu T, Ma D, Lu YP, Wang H: [Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma]. Chin J Cancer; 2010 Jan;29(1):15-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma].
  • BACKGROUND AND OBJECTIVE: The incidence of cervical adenosquamous carcinoma is relatively low.
  • This study was to analyze the clinicopathologic characteristics and prognostic factors of cervical adenosquamous carcinoma.
  • METHODS: Clinical data of 44 cervical adenosquamous carcinoma patients and 88 cervical adenocarcinoma patients(control), treated from January 2002 to December 2007, were analyzed using Chi-square test, Kaplan-Meier method, log-rank test, and Cox regression model.
  • RESULTS: The proportion of large tumors (maximal diameter > 4 cm) was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (47.7% vs. 28.4%, P<0.05); the proportion of poorly differentiated tumors was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (56.8% vs. 30.7%, P<0.05).
  • CONCLUSIONS: Cervical adenosquamous carcinoma is characterized by large tumor size and poor differentiation.
  • There is no difference in prognosis between cervical adenosquamous carcinoma and cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038304.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


3. Longatto-Filho A, Pinheiro C, Martinho O, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, Baltazar F, Reis RM: Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer; 2009 Jun 29;9:212
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.
  • BACKGROUND: Adenosquamous carcinoma of the uterine cervix is an infrequent but aggressive subtype of cervical cancer.
  • The objective of this study was to investigate EGFR, PDGFRA and VEGFR2 RTKs overexpression and activating gene mutations in a cohort of 30 adenosquamous carcinomas of the uterine cervix.
  • CONCLUSION: This is the most extensive analysis of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinomas.
  • Despite the absence of EGFR and PDGFRA activating mutations, the presence of overexpression of these three important therapeutic targets in a subset of cases may be important in predicting the sensitivity of adenosquamous carcinoma to specific anti-RTKs drugs.
  • [MeSH-major] Carcinoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Uterine Cervical Neoplasms / genetics. Vascular Endothelial Growth Factor Receptor-2 / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e19 [18232728.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35 [19037839.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Cancer. 2003 May 1;97(9):2196-202 [12712471.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):414-9 [12798704.001]
  • [Cites] Histopathology. 2003 Jul;43(1):33-9 [12823710.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2985-91 [12912946.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):346-53 [14599865.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):558-62 [14675676.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1366-74 [14977838.001]
  • [Cites] J Pathol. 2004 Mar;202(3):313-20 [14991896.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Biochemistry. 1987 Mar 10;26(5):1443-51 [3494473.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):149-53 [8459036.001]
  • [Cites] J Virol. 1993 Aug;67(8):4521-32 [8392596.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):433-40 [8697388.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):577-86 [10100709.001]
  • [Cites] Cell Mol Life Sci. 2004 Dec;61(23):2924-31 [15583854.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):207-10 [15791479.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2585-8 [15735736.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R788-95 [16168125.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Mod Pathol. 2006 May;19(5):701-7 [16557278.001]
  • [Cites] Clin Transl Oncol. 2006 Feb;8(2):77-82 [16632420.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):91-8 [16450401.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):407-20 [16890796.001]
  • [Cites] J Pathol. 2006 Aug;209(4):445-53 [16739104.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):235-41 [17581404.001]
  • [Cites] Drugs. 2007;67(14):2045-75 [17883287.001]
  • [Cites] Oncol Rep. 2007 Nov;18(5):1201-6 [17914573.001]
  • [Cites] Curr Med Chem. 2007;14(23):2495-516 [17979703.001]
  • [Cites] Oncol Rep. 2008 Jan;19(1):65-71 [18097577.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):42-6 [17980406.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):182-90 [18028988.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):203-8 [17827398.001]
  • [Cites] PLoS One. 2008;3(2):e1652 [18286204.001]
  • [Cites] Gynakol Geburtshilfliche Rundsch. 2008;48(2):94-100 [18431049.001]
  • [Cites] J Gastroenterol. 2008;43(7):499-508 [18648736.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jul-Aug;18(4):749-54 [17949425.001]
  • [Cites] BMC Cancer. 2008;8:232 [18700025.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S72-6 [18544460.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88 [18985183.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):350-5 [18708242.001]
  • [Cites] Drugs. 2000;60 Suppl 1:15-23; discussion 41-2 [11129168.001]
  • (PMID = 19563658.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2711112
  •  go-up   go-down


Advertisement
4. Cai HN, Wu XF, Xiang QY, Xiong YY, Zeng J: [Clinical analysis of 21 cases of cervical adenosquamous carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2008 Feb;43(2):124-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 21 cases of cervical adenosquamous carcinoma].
  • OBJECTIVE: To study the clinical characteristics, treatment modalities and prognosis of cervical adenosquamous carcinoma.
  • METHODS: The data of 21 patients with adenosquamous cervical cancer who were admitted into Zhongnan Hospital, Wuhan University from Jan 2001 to Dec 2005 were analyzed retrospectively.
  • CONCLUSIONS: Combined therapy should be given to patients with adenosquamous carcinoma of the cervix.
  • Surgical therapy and chemotherapy play an important role in the management and prognosis of adenoquamous carcinoma of cervix.
  • Preserve of ovary for patients with adenosquamous carcinoma of the cervix should only be done when the ovary is confirmed free from any malignant involvement by pathology.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy


5. Yoshida T, Sano T, Oyama T, Kanuma T, Fukuda T: Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma. Virchows Arch; 2009 Sep;455(3):253-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma.
  • Adenosquamous carcinoma of the uterine cervix is a rare mixture of malignant squamous and glandular epithelial elements and accounts for approximately 10% of cervical carcinomas.
  • The aims of the present study were to evaluate the prevalence, physical status, and viral load of HPV 16 and 18 in adenosquamous carcinoma.
  • Formalin-fixed paraffin-embedded tissue samples from 20 cases of histologically diagnosed adenosquamous carcinoma were examined.
  • The mean HPV 16 DNA copy numbers/cell was 7.22 in the squamous elements and 1.33 in the glandular elements (p=0.04) while the corresponding mean HPV 18 DNA copy numbers/cell was 1.50 and 0.89, respectively.
  • The prevalence of HPV 18 in adenosquamous carcinoma was high and many HPV 18-positive cases were the pure integrated form resulting in very low copy numbers/cell.
  • [MeSH-major] Carcinoma, Adenosquamous / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727809.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


6. Yan M, Zhang YN, He JH, Huang H: [Prognosis analysis of 83 cases of cervical adenosquamous carcinoma]. Ai Zheng; 2008 Sep;27(9):956-61
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis analysis of 83 cases of cervical adenosquamous carcinoma].
  • BACKGROUND & OBJECTIVE: Cervical adenosquamous carcinoma is a special histological type of cervical carcinoma.
  • This study was to explore the clinic-pathologic characteristics and prognostic factors of cervical adenosquamous carcinoma.
  • METHODS: Clinical data of 83 pathologically confirmed adenosquamous cervical carcinoma patients in Sun Yat-sen University Cancer Center from Nov.
  • CONCLUSIONS: Lymph node metastasis is an independent risk factor for prognosis in cervical adenosquamous carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / therapy. Hysterectomy / methods. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799035.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 56H9L80NIZ / Peplomycin; 74KXF8I502 / Aclarubicin; Q20Q21Q62J / Cisplatin; CAP therapy protocol
  •  go-up   go-down


7. Sasieni P, Castanon A, Cuzick J: Screening and adenocarcinoma of the cervix. Int J Cancer; 2009 Aug 1;125(3):525-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening and adenocarcinoma of the cervix.
  • Screening has had a major impact on cervical cancer in many countries.
  • Although there can be no doubt about its effectiveness in preventing squamous-cell carcinoma, there is little evidence of any benefit on adenocarcinoma and adenosquamous carcinoma of the cervix, and many authors have concluded that it is ineffective.
  • Among 3,305 cases with known histology, 641 had adenocarcinoma and 133 adenosquamous carcinoma.
  • The risk reduction associated with 3-yearly screening was greater for squamous carcinoma (75%, 95%CI 71-79%) and adenosquamous carcinoma (83%, 95%CI 68-91%) than for adenocarcinoma (43%, 95%CI 24-58%).
  • Among stage 1B+ cases, 83% (335/406) of women with adenocarcinoma had been screened within 10 years of diagnosis.
  • This is very similar to controls (82%, 3,292/3,965), but much higher than in women with squamous carcinoma (57%, 852/1,493).
  • Incidence of adenocarcinoma was low within 2.5 years of a negative smear (OR 2.3, 95%CI 0.15-0.34), but was no different from the background rates 4.5-5.5 years after a negative smear.
  • We conclude that screening has reduced the incidence of adenocarcinoma of the cervix, but the prognostic value of cytology is less (in both magnitude and duration) for adenocarcinoma than for squamous carcinoma.
  • The impact of screening on adenosquamous carcinoma is similar to its impact on squamous carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / prevention & control. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Mass Screening. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / prevention & control
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / prevention & control. Case-Control Studies. Colposcopy. Female. Great Britain / epidemiology. Humans. Incidence. Logistic Models. Middle Aged. Neoplasm Invasiveness


8. Li LJ, Wang ZQ, Wu BP: Peutz-Jeghers syndrome with small intestinal malignancy and cervical carcinoma. World J Gastroenterol; 2008 Dec 28;14(48):7397-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peutz-Jeghers syndrome with small intestinal malignancy and cervical carcinoma.
  • Because of small intestinal obstruction, she received the small intestinal polypectomy in 2001, and the pathological diagnosis was Peutz-Jeghers polyp canceration (mucinous adenocarcinoma, infiltrating full-thickness of the intestine).
  • We kept a follow-up study on her and found that she suffered from cervical cancer in 2007, with a pathological diagnosis of cervical adenosquamous carcinoma.The patient presented with typical features of PJS, but without a family history.
  • The PJS accompanied with both small intestinal and cervical malignancies has not been reported so far in the world.
  • [MeSH-major] Adenocarcinoma / complications. Carcinoma, Adenosquamous / complications. Ileal Neoplasms / complications. Peutz-Jeghers Syndrome / complications. Uterine Cervical Neoplasms / complications


9. Amălinei C, Balan R, Stolnicu S, Rădulescu D, Boeru C, Cotuţiu C: Adenosquamous cervical carcinoma morphological characteristics. Rev Med Chir Soc Med Nat Iasi; 2005 Apr-Jun;109(2):343-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous cervical carcinoma morphological characteristics.
  • Adenosquamous carcinomas range between 5-25% of cervical cancers and are composed by an admixture of malignant squamous and glandular elements.
  • Differential diagnosis with endometrioid adenocarcinoma of the cervix with squamous metaplasia was made.
  • Four cases (26.66%) were subtyped as clear cell adenosquamous carcinomas and 2 cases (13.33%) were subtyped as glassy cell carcinomas, exhibiting finely granular ground glass type cytoplasm.
  • One case presented extension to the uterine body.
  • One case, diagnosed as glassy cell subtype, presented regional lymph node metastases.
  • Our study concluded the occurrence of adenosquamous cervical carcinomas at a similar age with squamous cervical carcinomas in the investigated group of patients.
  • As adenosquamous cervical carcinomas are considered expressions of a biphasic differentiation of a single pluripotential sub-columnar reserve cell, a similar degree of differentiation of the two components would be expected.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607797.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


10. Neumann G, Rasmussen KL, Petersen LK: Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar. Obstet Gynecol; 2007 Aug;110(2 Pt 2):467-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar.
  • BACKGROUND: We report a rare case of a cervical adenosquamous carcinoma, initially diagnosed during delivery, with subsequent implantation in the episiotomy scar 5 weeks postpartum.
  • CASE: A 35-year-old woman with cervical adenosquamous carcinoma diagnosed during delivery was treated with radical abdominal hysterectomy with bilateral pelvic lymphadenectomy.
  • CONCLUSION: This case illustrates the importance of inspection of the perineal area during delivery in patients diagnosed with cervical cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Cicatrix / pathology. Episiotomy. Pregnancy Complications, Neoplastic / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local. Pregnancy. Puerperal Disorders / diagnosis. Puerperal Disorders / pathology. Puerperal Disorders / therapy


11. Smith HO, Jiang CS, Weiss GR, Hallum AV 3rd, Liu PY, Robinson WR 3rd, Cheng PC, Scudder SA, Markman M, Alberts DS: Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):298-305
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study.
  • The objective of this study was to determine objective response and overall survival (OS) and progression-free survival (PFS) following cisplatin plus tirapazamine treatment in eligible consenting patients with metastatic or recurrent squamous or adenosquamous carcinoma of the cervix.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445649.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 12213; United States / NCI NIH HHS / CA / CA 12644; United States / NCI NIH HHS / CA / CA 13612; United States / NCI NIH HHS / CA / CA 22433; United States / NCI NIH HHS / CA / CA 32102; United States / NCI NIH HHS / CA / CA 35090; United States / NCI NIH HHS / CA / CA 35178; United States / NCI NIH HHS / CA / CA 35192; United States / NCI NIH HHS / CA / CA 35262; United States / NCI NIH HHS / CA / CA 35431; United States / NCI NIH HHS / CA / CA 38926; United States / NCI NIH HHS / CA / CA 42777; United States / NCI NIH HHS / CA / CA 45450; United States / NCI NIH HHS / CA / CA 45461; United States / NCI NIH HHS / CA / CA 46136; United States / NCI NIH HHS / CA / CA 46441; United States / NCI NIH HHS / CA / CA 52654; United States / NCI NIH HHS / CA / CA 58861; United States / NCI NIH HHS / CA / CA 76132; United States / NCI NIH HHS / CA / CA 76448
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triazines; 1UD32YR59G / tirapazamine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Bolanca IK, Ciglar S: Evaluation of p16INK4a in cervical lesion of premenopausal and postmenopausal women. Coll Antropol; 2007 Apr;31 Suppl 2:107-11
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of p16INK4a in cervical lesion of premenopausal and postmenopausal women.
  • A total of 137 cervical specimens were enrolled in this study, of which 77 and 60 cervical smears were taken from premenopausal and postmenopausal women, respectively.
  • Two cervical smears were taken simultaneously in 68 women, one for conventional cytology and the other for immunostaining.
  • Additional 69 cervical smears were taken from the archive, decolorized and then used for immunostaining.
  • In premenopausal women 1 out of 14 (7.1%) with negative cytology, 7 out of 24 (29.2%) with low grade squamous intra-epithelial lesion (LSIL), all 35 (100%) with high grade squamous intraepithelial lesion (HSIL) and all 4 (100%) with squamous cell carcinoma (confirmed by histopathology) had positive staining to p16INK4a.
  • In postmenopausal women p16INK4a positivity was observed in 4 out of 7 (57.1%) cases of LSIL, 12 out of 14 (85.7%) cases of HSIL and all 4 out of 5 (80%) different cases of carcinoma (1 cervical adenosquamous carcinoma and 3 cervical squamous cell carcinoma in situ confirmed by histopathology), but none of 34 smears with normal cytology.
  • In the group of postmenopausal women, 16 out of 60 (26.7%) cases the cytological diagnosis was established on the basis of pl6lNK4a immunostaining as being HSIL.
  • From our preliminary study on a limited number of samples, we can however conclude that pl6INK4a immunostaining is a very useful tool for cytological diagnosis enabling to distinguish HSIL from normal, reactive or inflammatory changes.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16. Papanicolaou Test. Postmenopause. Premenopause. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears / classification


13. Cortés-Charry R, Figueira LM, Nieves L, Colmenter L: Metastasis detection with 18 FDG-positron emission tomography/computed tomography in gestational trophoblastic neoplasia: a report of 2 cases. J Reprod Med; 2006 Nov;51(11):897-901

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The imaging methods proposed by the International Consensus for the Diagnosis of Metastases in Trophoblastic Neoplasia are sufficient to stage the disease in most cases.
  • A 51-year-old woman was referred to the Hospital Universitario de Caracas from another hospital with a diagnosis of cervical adenosquamous carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17165437.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Schilder RJ, Blessing J, Cohn DE: Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2005 Jan;96(1):103-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
  • PURPOSE: A multicenter study was conducted to evaluate the activity and toxicity of gemcitabine in patients with previously treated non-squamous cell carcinoma of the uterine cervix.
  • Histologic confirmation of the primary diagnosis was mandatory.
  • One patient had a grade 4 gastrointestinal adverse event (rectovaginal fistula formation attributed to the underlying cancer and not the study agent) complicated by grade 4 metabolic derangement.
  • CONCLUSIONS: Gemcitabine as a single agent had minimal activity in previously treated patients with non-squamous cell carcinoma of the uterine cervix.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589587.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 13630; United States / NCI NIH HHS / CA / CA 23073; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 28160; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / CA13633; United States / NCI NIH HHS / CA / CA15977
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


15. Haider MA, Patlas M, Jhaveri K, Chapman W, Fyles A, Rosen B: Adenocarcinoma involving the uterine cervix: magnetic resonance imaging findings in tumours of endometrial, compared with cervical, origin. Can Assoc Radiol J; 2006 Feb;57(1):43-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma involving the uterine cervix: magnetic resonance imaging findings in tumours of endometrial, compared with cervical, origin.
  • PURPOSE: To determine the distinctive magnetic resonance imaging (MRI) features of cervical and endometrial adenocarcinoma that present clinically as a cervical mass.
  • MATERIALS AND METHODS: From 1999 to 2002, 56 patients with adenocarcinoma on the initial biopsy of a cervical mass underwent MRI at our institution.
  • A site of origin was determined by the pathologist in 38 of the 42 patients, and these were the cases evaluated; of these patients, 32 cases had adenocarcinoma and 6 had adenosquamous cancers.
  • RESULTS: Findings were significantly more prevalent in patients with adenocarcinomas of endometrial, compared with cervical, origin for endometrial thickening (11 [73%] and 3 [13%], respectively; P = 0.0003), endometrial mass (11 [73%] and 1 [4%], respectively; P < 0.0001), endometrial cavity expansion by a mass (9 [60%] and 2 [9%], respectively; P = 0.001), and invasion of myometrium from endometrium (9 [60%] and 0, respectively; P < 0.0001).
  • CONCLUSION: Adenocarcinomas of the endometrium that involve the cervix have MRI features that help distinguish them from primary adenocarcinomas of the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Cervix Uteri / pathology. Data Interpretation, Statistical. Diagnosis, Differential. Endometrium / pathology. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Neoplasm Staging. Reference Standards. Retrospective Studies. Sensitivity and Specificity


16. Vrdoljak E, Boraska Jelavic T, Saratlija-Novakovic Z, Hamm W: Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri. Eur J Gynaecol Oncol; 2005;26(6):602-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri.
  • The optimal treatment of women with locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri is still undefined.
  • We report a series of four consecutive patients with locally advanced adeno- or adenosquamous carcinomas of the uterine cervix (FIGO Stages IB-IIIB) treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by one to four cycles of consolidation chemotherapy with the same drug combination.
  • Despite the low number of patients in this series we may conclude that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy with the same drug combination is an efficacious treatment of patients with locally advanced adeno- or adenosquamous carcinomas of the cervix uteri.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / drug therapy. Uterine Cervical Neoplasms / drug therapy


17. Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, Pearl ML: Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol; 2005 Jan;96(1):108-11
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.
  • OBJECTIVE: The Gynecologic Oncology Group (GOG) has studied a number of drugs to determine their activity in patients with previously treated squamous and nonsquamous cancer arising in the uterine cervix.
  • CONCLUSION: With the dose schedule and assessment criteria employed, vinorelbine had only minimal activity in nonsquamous cancer of the cervix.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589588.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


18. Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Small W, Greven K: Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):111-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
  • PURPOSE: To determine the efficacy and patterns of initial failure for oral celecoxib, intravenous cisplatin, and 5-fluorouracil and concurrent pelvic radiotherapy in patients with locally advanced cancer of the cervix.
  • Of the 78 patients, 24 had treatment failure: 3 with persistent local disease, 9 local only, 2 regional, 4 distant, 1 regional and distant, 1 local and distant, and 2 with local, regional, and distant disease, and 1 had died of cervical cancer without a reported site of first failure and 1 without evidence of disease.
  • CONCLUSION: At 2 years, the estimated disease-free survival and overall survival rate for patients with advanced cervical cancer who underwent a combination of chemoradiotherapy and celecoxib treatment was 69% and 83%, respectively.
  • The identification of more active biologically targeted therapies is warranted for the treatment of advanced cancer of the cervix.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482376.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633; United States / NCI NIH HHS / CA / R01 CA106633-01; United States / NCI NIH HHS / CA / CA106633-02; United States / NCI NIH HHS / CA / R01 CA106633-02; United States / NCI NIH HHS / CA / CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633-04; United States / NCI NIH HHS / CA / CA106633-04; United States / NCI NIH HHS / CA / CA106633-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Zhao C, Florea A, Austin RM: Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med; 2010 Jan;134(1):103-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Atypical glandular cell (AGC) Papanicolaou (Pap) test interpretations are challenging.
  • Among the 75 cases with hrHPV+ AGC results, 13 (17.3%) had cervical intraepithelial neoplasia grades 2/3, 10 (13.3%) had adenocarcinoma in situ, and 3 (4.0%) had cervical invasive adenocarcinoma, whereas for 234 women with hrHPV(-) results, 1 (0.4%) had cervical intraepithelial neoplasia grades 2/3, 1 (0.4%) had adenocarcinoma in situ, 1 each (0.4%) had cervical adenocarcinoma and ovarian carcinoma, and 8 (3.4%) had endometrial carcinoma.
  • CONCLUSIONS: Positive hrHPV AGC results were most strongly associated with cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ in women younger than 50 years.
  • Positive hrHPV AGC results were also present in all 3 cases of invasive cervical adenocarcinoma in women younger than 50 years.
  • Of note, hrHPV(-) AGC results were present in 10 of 13 carcinomas (76.9%) detected after AGC Pap tests, all in women 40 years or older with endometrial adenocarcinomas (n = 8), ovarian carcinoma (n = 1), and cervical adenosquamous carcinoma in a woman (n = 1) in her 50s.
  • Testing for hrHPV after AGC Pap testing was most helpful in the detection of cervical intraepithelial neoplasia grades 2/3, adenocarcinoma in situ, and invasive cervical adenocarcinomas in women younger than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. DNA, Viral. Papanicolaou Test. Papillomaviridae / genetics. Uterine Cervical Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / virology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / virology. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / virology. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073612.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


20. Lewis H, Yeh LC, Almendral B, Neal H: Monitoring the performance of New Zealand's National Cervical Screening Programme through data linkage. N Z Med J; 2009 Oct 30;122(1305):15-25
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring the performance of New Zealand's National Cervical Screening Programme through data linkage.
  • AIM: To describe the method developed by the National Cervical Screening Programme (NCSP) for review of cases of cervical cancer; present results from the first 4 years of the review and compare these results with those of the earlier New Zealand Cervical Cancer Audit.
  • METHODS: Linkage of cervical cancer registrations from the New Zealand Cancer Registry to smear histories from the NCSP Register via the National Health Index, for the 4-year period 2003-06.
  • RESULTS: A total of 625 women were registered with cervical cancer from 2003-06, of whom 438 were eligible for linkage (women diagnosed with squamous or adenosquamous cervical cancer at <80 years of age).
  • Linkage to screening history revealed that 202 of the 438 eligible women (46%) had never been enrolled in the NCSP; 137 (31%) were enrolled but had only been infrequently or irregularly screened; and 85 (20%) developed cancer despite regular screening (data were missing for 3 women).
  • These results were similar to those found in the New Zealand Cervical Cancer Audit, covering the period 2000-2002.
  • CONCLUSIONS: Ongoing linkage of cancer data to screening data can be used to monitor the performance of the NCSP.
  • Our finding that 80% of potentially preventable cervical cancers involve women who are not enrolled in the Programme or who have been only infrequently and irregularly screened, confirms that improving Programme coverage (currently around 72%) remains a priority.
  • Further investigation (phase 2) is required for the small number of women who develop cervical cancer despite regular screening (average of 21 per year, or approximately 20% of eligible cases), to distinguish interval cancers from possible Programme quality issues.
  • [MeSH-major] Mass Screening / statistics & numerical data. Medical Record Linkage. Quality Assurance, Health Care / methods. Registries / statistics & numerical data. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / prevention & control


21. Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO, Gynecologic Oncology Group: Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2008 Jul;110(1):65-70
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
  • OBJECTIVE: To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity.
  • Patients must have had advanced or recurrent measurable carcinoma of the cervix, and failed one prior chemotherapy regimen.
  • CONCLUSION: Pemetrexed at this dose and schedule showed moderate activity against advanced or recurrent cervical cancer that has failed prior chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Dexamethasone / therapeutic use. Disease Progression. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Middle Aged. Neoplasm Recurrence, Local. Patient Selection. Pemetrexed. Treatment Outcome


22. Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ: A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer. Gynecol Oncol; 2009 Jan;112(1):85-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
  • OBJECTIVES: Topotecan improves response rate (RR), progression-free survival (PFS) and overall survival (OS) when added to cisplatin in treating metastatic and recurrent cervical cancer.
  • The objective of this study was to assess the feasibility of adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation.
  • METHODS: Patients with primary, previously untreated, histologically confirmed invasive squamous cell, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, stages IB2-IVA were treated with external beam pelvic radiotherapy (45 Gy), intracavitary low dose rate brachytherapy (40 Gy) and a parametrial boost (5.4-9 Gy) with overall treatment time not to exceed 8 weeks.
  • CONCLUSIONS: The addition of weekly topotecan to cisplatin at this dose and schedule during pelvic irradiation for locally advanced cervical cancer appears to be feasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Brachytherapy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Humans. Middle Aged. Neoplasm Staging. Survival Rate. Topotecan / administration & dosage. Topotecan / adverse effects


23. Takeshima N, Umayahara K, Fujiwara K, Hirai Y, Takizawa K, Hasumi K: Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer. Gynecol Oncol; 2006 Nov;103(2):618-22
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.
  • OBJECTIVE: To determine the effectiveness of chemotherapy alone as postoperative adjuvant therapy for intermediate- and high-risk cervical cancer.
  • METHODS: The study group comprised of 65 consecutive patients with stage IB or IIA squamous cell or adenosquamous cervical cancer who were initially treated with radical hysterectomy and pelvic lymphadenectomy between 1993 and 2002.
  • RESULTS: Estimated 5-year disease-free survival was 93.3% for the 30 patients with intermediate-risk tumors (100% for those with squamous cell carcinoma and 71.4% for those with adenosquamous carcinoma) and 85.7% for the 35 patients with high-risk tumors (89.3% for those with squamous cell carcinoma and 71.4% for those with adenosquamous carcinoma).
  • CONCLUSIONS: The treatment results suggest the potential role of adjuvant chemotherapy alone for patients with cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Staging. Risk Factors. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects


24. Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Greven K: A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):104-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
  • PURPOSE: To determine treatment-related acute toxicity rates in patients with locally advanced cervical cancer treated by oral celecoxib, i.v. cisplatin and 5-FU, and concurrent pelvic radiation therapy.
  • METHODS AND MATERIALS: Eligible patients on this RTOG Phase I-II study for advanced cervix cancer included FIGO Stage IIB-IVA or patients with FIGO Stage IB through IIA with biopsy proven pelvic node metastases or tumor size > or =5 cm.
  • Albeit, the toxicity was deemed excessive in this trial, the rate of toxicities was not too different compared to other recent experiences with concurrent chemoradiation for advanced cervix cancer.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084549.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633; United States / NCI NIH HHS / CA / R01 CA106633-01; United States / NCI NIH HHS / CA / CA106633-02; United States / NCI NIH HHS / CA / R01 CA106633-02; United States / NCI NIH HHS / CA / CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633-04; United States / NCI NIH HHS / CA / CA106633-04; United States / NCI NIH HHS / CA / CA106633-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Chumworathayi B, Suprasert P, Charoenkwan K, Srisomboon J, Phongnarisorn C, Siriaree S, Cheewakriangkrai C, Tantipalakorn J, Kiatpeerakul C, Pantusart A: Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: a randomized comparison of treatment compliance. J Med Assoc Thai; 2005 Nov;88(11):1483-92
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: a randomized comparison of treatment compliance.
  • OBJECTIVES: To compare weekly and three-weekly cisplatin as an adjunct to radiation therapy in high-risk early-stage cervical cancer after surgery with regard to treatment compliance.
  • MATERIAL AND METHOD: From June 1st, 2003 to February 29th, 2004, the authors performed a randomized trial of radiotherapy in combination with two concurrent chemotherapy regimens - weekly or three-weekly cisplatin--in patients with high-risk cervical cancer FIGO stage I-IIA after surgery.
  • Women with primary invasive squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix were enrolled.
  • CONCLUSION: Concurrent chemoradiation with weekly cisplatin regimen has more complete treatment rate and less delayed courses than that with three- weekly cisplatin among women with high-risk cervical cancer after surgery.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Patient Compliance. Uterine Cervical Neoplasms / drug therapy


26. Lennerz JK, Perry A, Mills JC, Huettner PC, Pfeifer JD: Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion. Am J Surg Pathol; 2009 Jun;33(6):835-43
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion.
  • Mucoepidermoid carcinoma (MEC) of the uterine cervix is a controversial entity.
  • By strict morphologic criteria, the tumor has features identical to those of salivary gland MEC and is characterized by nests composed of 3 cell types (epidermoid, intermediate, and mucin producing) in the absence of overt glandular differentiation.
  • Nonetheless, the entity is not recognized in the current World Health Organization classification of cervical tumors.
  • Given the morphologic similarity between MEC of the cervix and MEC of the salivary glands, we sought to determine if MEC of the cervix harbors the t(11;19)(q21;p13) characteristic of MEC of the major and minor salivary glands, a rearrangement that results in fusion of the cyclic adenosine 3',5' monophosphate coactivator CRTC1 to the Notch coactivator MAML2.
  • We identified 7 cervical tumors from our departmental files and performed reverse transcription-polymerase chain reaction and fluorescence in situ hybridization-based molecular analysis for rearrangements of CRTC1 and MAML2; 14 conventional cervical adenosquamous carcinomas were used as controls.
  • Analysis of the cervical MECs demonstrated a CRTC1-MAML2 fusion in 1 case, rearrangements of CRTC1 in 4 cases, and aberrations of MAML2 in 5 cases (rearrangements in 2 cases, amplification in 3 cases).
  • All MEC showed aberrations of at least 1 of the loci, whereas none of the cervical adenosquamous carcinomas harbored rearrangements or amplification of either locus.
  • Our results demonstrate that cervical tumors defined as MEC by strict morphologic criteria harbor genetic aberrations involving the genes characteristically rearranged in MEC of the salivary glands, and suggest that cervical MEC is an entity distinct from conventional cervical adenosquamous carcinoma.
  • The development of drug therapy targeted to the genes rearranged in MEC underscores the importance of correct classification of cervical MEC because the diagnosis may hold therapeutic implications different from other cervical malignancies.

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092631.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062; United States / NIDDK NIH HHS / DK / R01 DK079798; United States / NIDDK NIH HHS / DK / R01 DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062-05; United States / NIDDK NIH HHS / DK / DK066062-05
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


27. Chen JR, Lee YJ, Chen T, Wang KL, Dang CW, Chang SC, Liu HF, Yang YC: MHC class I chain-related gene A (MICA) polymorphism and the different histological types of cervical cancer. Neoplasma; 2005;52(5):369-73
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MHC class I chain-related gene A (MICA) polymorphism and the different histological types of cervical cancer.
  • Cervical cancer has been one of the most important gynecologic cancer in Taiwan with incidence of 24/100,000 and mortality of 8.7/100,000 annually.
  • About 70-80% are squamous cell carcinoma; the remainder are composed of various types of adenocarcinoma, adenosquamous carcinoma and undifferentiated carcinoma.
  • Although MICA was not associated with cervical cancer in the study of Northern Sweden, there are no further studies about the association of MICA polymorphism and the different histological types of cervical cancer.
  • We analyzed the MICA polymorphism in 110 cervical cancer cases (88 squamous cell carcinoma, 12 adenocarcinoma and 10 adenosquamous carcinoma) and 82 randomly selected unrelated controls from 1994 to 2000 in the Mackay Memorial Hospital, Taipei, Taiwan.
  • DNA was extracted part from leukocytes of peripheral blood, part from tumor tissue and 5 polymorphic microsatellite alleles (A4,A5,A5.1,A6,A9) of MICA were identified by a polymerase chain reaction-based (PCR) technique using ABI Prism 377-18 DNA sequencer (Applied Biosystems, Foster City, CA, USA).
  • There was no association with cervical cancer patients and non-cervical cancer patients (p=0.337, 0.356 and 0.414).
  • After dividing the cervical cancer patients into 3 major histological types (squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma), the result was still the same (p=0.598, 0.172 and 0.617) in our study.
  • We found no association between MICA gene polymorphism and cervical cancer in Taiwan.
  • Different histological types of cervical cancer also have no significant correlation with MICA gene polymorphism.
  • It demonstrates that polymorphism of MICA gene bears no relation to cervical cancer and the different histological types of cervical cancer in Taiwan.
  • We need further studies for identifying the factors causing the differentiation of cancer cells of the uterine cervix.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / genetics. Histocompatibility Antigens Class I / genetics. Polymorphism, Genetic. Uterine Cervical Neoplasms / genetics

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16151576.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class I; 0 / MHC class I-related chain A
  •  go-up   go-down


28. Zhang Z, Borecki I, Nguyen L, Ma D, Smith K, Huettner PC, Mutch DG, Herzog TJ, Gibb RK, Powell MA, Grigsby PW, Massad LS, Hernandez E, Judson PL, Swisher EM, Crowder S, Li J, Gerhard DS, Rader JS: CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res; 2007 Dec 1;67(23):11202-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer.
  • We previously mapped a nonrandom frequent loss of heterozygosity (LOH) region in cervical cancers to 1 Mb of 6p23.
  • Here, we describe the identification of a novel cervical cancer susceptibility gene, CD83.
  • Investigation of CD83 uncovered three alternative transcripts in cervical tissue and cell lines, with variant 3 (lacking exons 3 and 4) being more frequent in cervical cancer than in normal cervical epithelium (P = 0.0181).
  • Genomic sequencing on 36 paired normal and cervical tumors revealed several somatic mutations and novel SNPs in the promoter, exons, and introns of CD83.
  • LOH was confirmed in >90% of cervical cancer specimens.
  • Immunofluorescence colocalized CD83 protein to the Golgi apparatus and cell membrane of cervical cancer cell lines.
  • None of seven nearby genes was differentially expressed in cervical cancer.
  • The importance of CD83 in epithelial versus dendritic cells needs to be determined, as does its role in promoting cervical cancer.
  • [MeSH-major] Antigens, CD / genetics. Genetic Predisposition to Disease. Immunoglobulins / genetics. Membrane Glycoproteins / genetics. Polymorphism, Single Nucleotide. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / virology. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / genetics. Cervical Intraepithelial Neoplasia / pathology. Cervical Intraepithelial Neoplasia / virology. Cervix Uteri / metabolism. Cervix Uteri / pathology. Chromosomes, Human, Pair 6 / genetics. Exons. Expressed Sequence Tags. Female. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Genotype. Humans. Loss of Heterozygosity. Neoplasm Invasiveness / pathology. Papillomaviridae / genetics. Papillomavirus Infections / genetics. Papillomavirus Infections / pathology. Papillomavirus Infections / virology. Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056445.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R01CA094141; United States / NCI NIH HHS / CA / 5R01CA095713
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD83 antigen; 0 / Immunoglobulins; 0 / Membrane Glycoproteins
  •  go-up   go-down


29. Stehman FB, Ali S, Keys HM, Muderspach LI, Chafe WE, Gallup DG, Walker JL, Gersell D: Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol; 2007 Nov;197(5):503.e1-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.
  • OBJECTIVE: The objective of the study was to confirm that concurrent cisplatin (CT) with radiation therapy (RT) is associated with improved long-term progression-free survival (PFS) and overall survival (OS), compared with RT alone in stage IB bulky carcinoma of the cervix, when both groups' therapy is followed by hysterectomy.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):872-80 [14990643.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):973-82 [7860414.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):721-8 [15721417.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8289-95 [16230678.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):296-304 [16376417.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):941-52 [8083095.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • [Cites] Lancet. 2001 Sep 8;358(9284):781-6 [11564482.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):966-72 [11844818.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):343-53 [12798694.001]
  • [CommentIn] Am J Obstet Gynecol. 2007 Nov;197(5):443-4 [17980175.001]
  • (PMID = 17980189.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA027469-27; United States / NCI NIH HHS / CA / U10 CA037517-23; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA027469-27; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS34241; NLM/ PMC2112746
  •  go-up   go-down


30. Grizzle WE, Srivastava S, Manne U: The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark; 2010;9(1-6):21-39
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For some organs, such as the oral cavity, cervix and skin, the respective putative pre-invasive lesions can be observed over time and documented to progress to invasive lesions.
  • However, for less readily observable lesions, such as those of the prostate, the progression of the pre-invasive lesions, e.g., prostatic intraepithelial neoplasia (PIN) and prostatic proliferative inflammatory atrophy (PIA) to prostatic cancer are more difficult to document.
  • 1) microinvasive disease developing from a pre-invasive neoplastic lesion, 2) the general association of the pre-invasive lesion with invasive lesions, 3) the subsequent development of invasive lesions following diagnosis of the pre-invasive lesion, 4) correlations of the molecular features of the putative pre-invasive lesion with the matching invasive lesions, and 5) reductions in the rate of cancer following removal of the pre-invasive lesion.
  • It is now commonly accepted that these lesions are a features of the spectrum of neoplastic development and most are accepted as ``neoplastic lesions'' with associated molecular features, even though they may be reversible even if they have mutations in suppressor genes (e.g., p53) or are associated with viral etiologies (e.g., cervical intraepithelial neoplasia).
  • The term "intra-epithelial neoplasia" with an associated grade, which has been developed for pre-invasive neoplastic lesions of the cervix, i.e. cervical intraepithelial neoplasia (CIN), seems to be a terminology that adds consistency across epithelial organs.
  • An excellent example of this is ulcerative colitis (UC) in which dysregulation of microsatellite repair enzymes have been documented one year following diagnosis of UC.
  • While the nomenclature, description, diagnosis and etiology of pre-invasive neoplasia has advanced, approaches to therapy of such lesions have not progressed adequately even though it has been identified that, for example, removal of polyps periodically from the colorectum, DCIS from the breast, and high grade CIN from the cervix, results in a reduction in the development of cancers of the colorectum, breast, and cervix, respectively.
  • [MeSH-major] Carcinoma in Situ / etiology
  • [MeSH-minor] Animals. Carcinoma, Adenosquamous / etiology. Carcinoma, Squamous Cell / etiology. Cell Transformation, Neoplastic / chemically induced. Cell Transformation, Neoplastic / radiation effects. Disease Progression. Environmental Exposure. Humans. Immunologic Surveillance. Metagenome. Mice. Neoplasm Regression, Spontaneous. Neoplasms, Experimental / etiology. Neoplastic Stem Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem Suppl. 1994;19:259-66 [7823598.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):751-8 [6275978.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4264-7 [7671233.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1237-40 [8640805.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1197-200 [8630897.001]
  • [Cites] Eur Urol. 1996;30(2):153-66 [8875196.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9 [8943054.001]
  • [Cites] J Histochem Cytochem. 2008 Mar;56(3):305-12 [18071066.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2813-20 [18539959.001]
  • [Cites] Pathobiology. 2008;75(2):75-84 [18544962.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1361-5 [18703712.001]
  • [Cites] JAMA. 2008 Oct 1;300(13):1523-31 [18827209.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Arch Pathol Lab Med. 1986 Nov;110(11):1076-9 [3778125.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Carcinogenesis. 1990 Aug;11(8):1393-8 [2167183.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):644-52 [1712748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1621-6 [10362784.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1825-30 [10362807.001]
  • [Cites] Head Neck. 1999 Sep;21(6):566-73 [10449674.001]
  • [Cites] Jpn J Cancer Res. 1999 Jul;90(7):711-9 [10470282.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1375-85 [16424164.001]
  • [Cites] Lab Invest. 2006 Feb;86(2):175-90 [16402033.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R897-908 [16280039.001]
  • [Cites] Nat Med. 2006 Aug;12(8):875-8 [16892025.001]
  • [Cites] Blood. 2007 May 15;109(10):4336-42 [17244679.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6867-75 [17513735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13732-7 [17702869.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8121-30 [17804724.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3407-16 [17666570.001]
  • [Cites] Nat Med. 1997 May;3(5):510-4 [9142118.001]
  • [Cites] Biotech Histochem. 1997 Mar;72(2):96-104 [9152522.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jul;19(3):170-5 [9218998.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 1;90(7):523-31 [9539248.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):597-9 [10203598.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] J Invest Dermatol. 1993 Jun;100(6):746-8 [8496613.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] N Engl J Med. 1994 Jan 20;330(3):159-64 [8264737.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):765-78 [8037290.001]
  • [Cites] J Immunol. 2008 Oct 15;181(8):5242-8 [18832678.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Breast Dis. 2008;29:27-36 [19029622.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):678-86 [19147584.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1302-13 [19190339.001]
  • [Cites] Nat Rev Immunol. 2009 Mar;9(3):162-74 [19197294.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2621-33 [19235923.001]
  • [Cites] Cancer Biomark. 2010;9(1-6):41-64 [22112469.001]
  • [Cites] Cancer Biomark. 2010;9(1-6):177-92 [22112476.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] J Immunol Methods. 2001 Jan 1;247(1-2):163-74 [11150547.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3230-9 [11309271.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1247-53 [11583952.001]
  • [Cites] Gut. 2002 Apr;50(4):520-4 [11889073.001]
  • [Cites] Nat Rev Immunol. 2002 Aug;2(8):569-79 [12154376.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):149-58 [12168960.001]
  • [Cites] Immunol Allergy Clin North Am. 2003 Feb;23(1):83-102, vi [12645880.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6369-76 [14508517.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Am J Gastroenterol. 1995 Mar;90(3):353-65 [7872270.001]
  • (PMID = 22112468.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / P30 AR050948; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / P50 CA101955; United States / NCI NIH HHS / CA / U24 CA086359
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS402045; NLM/ PMC3430522
  •  go-up   go-down


31. Maley SN, Schwartz SM, Johnson LG, Malkki M, Du Q, Daling JR, Li SS, Zhao LP, Petersdorf EW, Madeleine MM: Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study. Int J Immunogenet; 2009 Dec;36(6):367-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study.
  • We conducted a population-based case-control study to test the hypothesis that common genetic variation in CXCL12 individual single nucleotide polymorphism (SNP) alleles and haplotypes] is associated with the risk of cervical carcinoma.
  • Cases (n = 917) were residents of western Washington State diagnosed with invasive squamous cell cervical carcinoma (SCC), invasive adenocarcinoma or adenosquamous carcinoma, or adenocarcinoma in situ of the cervix.
  • The minor allele of intronic SNP rs266085 was inversely associated with cervical cancer under a recessive genetic effects model (OR = 0.74, 95% CI: 0.56-0.98).
  • A stepwise procedure identified rs17885289, rs266085 and 3'-untranslated region (UTR) SNP rs266093 as the most parsimonious subset of SNPs necessary to define the haplotype inversely associated with cervical cancer risk in our study.
  • A 3'-UTR SNP, rs1801157, previously found to be related to HIV pathogenesis, was not associated with cervical cancer risk.
  • Further population-based studies are warranted to confirm these associations between genetic variation in CXCL12 and cervical cancer risk.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Mar 1;107(5):1761-7 [16269611.001]
  • [Cites] Tissue Antigens. 2006 Feb;67(2):127-33 [16441483.001]
  • [Cites] Int J Mol Med. 2006 Oct;18(4):785-93 [16964435.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):478-83 [17362322.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):577-86 [17366619.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5056-62 [17785557.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1652-8 [17894551.001]
  • [Cites] Oncol Rep. 2007 Dec;18(6):1583-7 [17982648.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3532-9 [18451182.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1790-9 [18628433.001]
  • [Cites] BMC Genet. 2008;9:90 [19102730.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1117-21 [10613347.001]
  • [Cites] Eur J Neurosci. 2000 Jun;12(6):1857-66 [10886327.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2597-606 [12239174.001]
  • [Cites] Am J Epidemiol. 2003 Feb 1;157(3):218-26 [12543621.001]
  • [Cites] Nat Genet. 2003 May;34(1):70-4 [12692554.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] Biostatistics. 2003 Oct;4(4):513-22 [14557108.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]
  • [Cites] J Med Genet. 2004 May;41(5):e59 [15121787.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):233-45 [15339043.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):829-33 [8752280.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):541-8 [8827359.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1101-9 [9064327.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):381-6 [9833747.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Immunol Rev. 2005 Feb;203:235-43 [15661033.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):493-5 [15686457.001]
  • [Cites] J Infect Dis. 2005 Mar 15;191(6):969-76 [15717274.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1069-75 [15809352.001]
  • [Cites] J Mol Biol. 2005 Apr 22;348(1):43-62 [15808852.001]
  • [Cites] Hum Mol Genet. 2005 Jun 15;14(12):1579-85 [15843397.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):261-6 [15978329.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):311-5 [15955592.001]
  • [Cites] Tissue Antigens. 2005 Oct;66(4):321-4 [16185329.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):276-9 [16249700.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):521-6 [16284526.001]
  • [Cites] Genes Immun. 2005 Dec;6(8):691-8 [16177829.001]
  • [Cites] Gene. 2006 Jun 7;374:174-9 [16626895.001]
  • (PMID = 19788587.001).
  • [ISSN] 1744-313X
  • [Journal-full-title] International journal of immunogenetics
  • [ISO-abbreviation] Int. J. Immunogenet.
  • [Language] ENG
  • [Grant] United States / NHGRI NIH HHS / HG / T32HG00035; United States / NCI NIH HHS / CA / CA112512-02; United States / NCI NIH HHS / CA / R01CA112512; United States / NCI NIH HHS / CA / R01 CA112512-02; United States / NCI NIH HHS / CA / P01 CA042792-219003; United States / NCI NIH HHS / CA / P01CA04279; United States / NCI NIH HHS / CA / R25 CA094880; United States / NCI NIH HHS / CA / CA112512-01; United States / NIEHS NIH HHS / ES / P30ES07033; United States / NHGRI NIH HHS / HG / T32 HG000035; United States / NCI NIH HHS / CA / CA112512-04; United States / NCI NIH HHS / CA / R01 CA112512-01; United States / NCI NIH HHS / CA / R01 CA112512-03; United States / NIEHS NIH HHS / ES / P30 ES007033; United States / NCI NIH HHS / CA / R01 CA112512-04; United States / NCI NIH HHS / CA / R25CA094880; United States / NCI NIH HHS / PC / N01-PC-35412; United States / NCI NIH HHS / CA / CA042792-219003; United States / NCI NIH HHS / CA / P01 CA042792; United States / NCI NIH HHS / CA / CA112512-03; United States / NCI NIH HHS / CA / CA112512-05; United States / NCI NIH HHS / CA / R01 CA112512-05; United States / NCI NIH HHS / CA / R01 CA112512
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12
  • [Other-IDs] NLM/ NIHMS144226; NLM/ PMC2784202
  •  go-up   go-down


32. Baltazar F, Filho AL, Pinheiro C, Moreira MA, Queiroz GS, Oton GJ, Júnior AF, Ribeiro LF, Schmitt FC: Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. Int J Gynecol Pathol; 2007 Jul;26(3):235-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas.
  • This study was designed to evaluate the significance of cyclooxygenase (COX)-2 and epidermal growth factor receptor (EGFR) expression in a series of cervical adenocarcinoma (AC), cervical adenosquamous carcinoma (ASC), and cervical squamous cell carcinoma (SCC).
  • One hundred thirty cases of cervical carcinoma (30 ASC, 50 AC, and 50 SCC) were analyzed for COX-2 and EGFR expressions using specific primary antibodies.
  • The COX-2 expression was more frequently positive than EGFR in all cervical cancers studied.
  • There was no significant correlation between COX-2 and EGFR expressions and age at diagnosis, recurrence, distant metastasis, and/or positive status of regional lymph nodes, neither between COX-2 and EGFR coexpression and the clinical data analyzed.
  • Nevertheless, our data support that there are significant differences between EGFR and COX-2 expressions in the 3 different histogenetic types of cervical cancer.
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma, Adenosquamous / enzymology. Carcinoma, Squamous Cell / enzymology. Cyclooxygenase 2 / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. Uterine Cervical Neoplasms / enzymology


33. Fumerton R, Afifi T, Martinka M, de Gannes G: Cutaneous metastases of cervical adenosquamous carcinoma. J Am Acad Dermatol; 2010 Aug;63(2):e48-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastases of cervical adenosquamous carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Cervical Intraepithelial Neoplasia / pathology. Skin Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20633787.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down






Advertisement